Wintermute Biomedical, Inc.

United States of America

Back to Profile

1-15 of 15 for Wintermute Biomedical, Inc. Sort by
Query
Aggregations
IP Type
        Patent 14
        Trademark 1
Jurisdiction
        United States 10
        World 3
        Canada 2
Date
2025 November 1
2025 (YTD) 2
2023 1
2022 2
2021 2
See more
IPC Class
A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA] 14
A61K 31/201 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having one or two double bonds, e.g. oleic or linoleic acid 12
A61P 31/04 - Antibacterial agents 11
A61K 9/00 - Medicinal preparations characterised by special physical form 8
A01N 33/12 - Quaternary ammonium compounds 7
See more
Status
Pending 4
Registered / In Force 11

1.

THERAPEUTIC COMPOSITIONS

      
Application Number 19192157
Status Pending
Filing Date 2025-04-28
First Publication Date 2025-11-13
Owner Wintermute Biomedical, Inc. (USA)
Inventor
  • Rau, Thomas F.
  • Rogers, Geoffrey W.

Abstract

Compositions of fatty acids (e.g., including one or more C4 to C40 fatty acids, such as a C4 to C20 fatty acid) and one or more amino acids (and particularly one or more amino acids having electrically charged basic side chains, e.g., Arginine, Lysine, etc.) for use as an anti-pathogenic composition. These compositions may find particular use as anti-bacterial and in some variations anti-viral, anti-fungal and anti-cancer compositions.

IPC Classes  ?

  • A61K 31/20 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid
  • A01N 33/12 - Quaternary ammonium compounds
  • A01N 37/06 - Unsaturated carboxylic acids or thio-analogues thereofDerivatives thereof
  • A01N 37/44 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing at least one carboxylic group or a thio-analogue, or a derivative thereof, and a nitrogen atom attached to the same carbon skeleton by a single or double bond, this nitrogen atom not being a member of a derivative or of a thio-analogue of a carboxylic group, e.g. amino-carboxylic acids
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 31/14 - Quaternary ammonium compounds, e.g. edrophonium, choline
  • A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
  • A61K 31/201 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having one or two double bonds, e.g. oleic or linoleic acid
  • A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
  • A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
  • A61P 31/02 - Local antiseptics
  • A61P 31/04 - Antibacterial agents

2.

THERAPEUTIC METHODS USING DECANOIC ACID AND AMINO ACIDS

      
Application Number 19011583
Status Pending
Filing Date 2025-01-06
First Publication Date 2025-07-31
Owner Wintermute Biomedical, Inc. (USA)
Inventor
  • Rau, Thomas F.
  • Rogers, Geoffrey W.

Abstract

Compositions including a complex of fatty acids (e.g., including one or more C4 to C40 fatty acids, such as a C4 to C20 fatty acid) and one or more amino acids (and particularly one or more amino acids having electrically charged basic side chains, e.g., Arginine, Lysine, etc.) for use as an anti-pathogenic composition. In particular, described herein are compositions of decanoic acid:Arginine in which the decanoic acid and Arginine for a complex having a lamellar supramolecular structure.

IPC Classes  ?

  • A61K 31/20 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid
  • A01N 33/12 - Quaternary ammonium compounds
  • A01N 37/06 - Unsaturated carboxylic acids or thio-analogues thereofDerivatives thereof
  • A01N 37/44 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing at least one carboxylic group or a thio-analogue, or a derivative thereof, and a nitrogen atom attached to the same carbon skeleton by a single or double bond, this nitrogen atom not being a member of a derivative or of a thio-analogue of a carboxylic group, e.g. amino-carboxylic acids
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 31/14 - Quaternary ammonium compounds, e.g. edrophonium, choline
  • A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
  • A61K 31/201 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having one or two double bonds, e.g. oleic or linoleic acid
  • A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
  • A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
  • A61P 31/02 - Local antiseptics
  • A61P 31/04 - Antibacterial agents

3.

SOLEXAN

      
Serial Number 97924284
Status Pending
Filing Date 2023-05-07
Owner Wintermute Biomedical Incorporated ()
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Pharmaceutical preparations for the treatment of blisters on the skin associated with shingles

4.

Therapeutic methods using decanoic acid and amino acids

      
Application Number 17510326
Grant Number 12186293
Status In Force
Filing Date 2021-10-25
First Publication Date 2022-02-10
Grant Date 2025-01-07
Owner Wintermute Biomedical, Inc. (USA)
Inventor
  • Rau, Thomas F.
  • Rogers, Geoffrey W.

Abstract

Compositions including a complex of fatty acids (e.g., including one or more C4 to C40 fatty acids, such as a C4 to C20 fatty acid) and one or more amino acids (and particularly one or more amino acids having electrically charged basic side chains, e.g., Arginine, Lysine, etc.) for use as an anti-pathogenic composition. In particular, described herein are compositions of decanoic acid: Arginine in which the decanoic acid and Arginine for a complex having a lamellar supramolecular structure.

IPC Classes  ?

  • A61K 31/20 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid
  • A01N 33/12 - Quaternary ammonium compounds
  • A01N 37/06 - Unsaturated carboxylic acids or thio-analogues thereofDerivatives thereof
  • A01N 37/44 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing at least one carboxylic group or a thio-analogue, or a derivative thereof, and a nitrogen atom attached to the same carbon skeleton by a single or double bond, this nitrogen atom not being a member of a derivative or of a thio-analogue of a carboxylic group, e.g. amino-carboxylic acids
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
  • A61K 31/201 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having one or two double bonds, e.g. oleic or linoleic acid
  • A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
  • A61P 31/02 - Local antiseptics
  • A61P 31/04 - Antibacterial agents
  • A61K 31/14 - Quaternary ammonium compounds, e.g. edrophonium, choline
  • A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

5.

Therapeutic compositions

      
Application Number 17282185
Grant Number 12324797
Status In Force
Filing Date 2019-10-01
First Publication Date 2022-01-06
Grant Date 2025-06-10
Owner Wintermute Biomedical, Inc. (USA)
Inventor
  • Rau, Thomas F.
  • Rogers, Geoffrey W.

Abstract

Compositions of fatty acids (e.g., including one or more C4 to C40 fatty acids, such as a C4 to C20 fatty acid) and one or more amino acids (and particularly one or more amino acids having electrically charged basic side chains, e.g., Arginine, Lysine, etc.) for use as an anti-pathogenic composition. These compositions may find particular use as anti-bacterial and in some variations anti-viral, anti-fungal and anti-cancer compositions.

IPC Classes  ?

  • A61K 31/20 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid
  • A01N 33/12 - Quaternary ammonium compounds
  • A01N 37/06 - Unsaturated carboxylic acids or thio-analogues thereofDerivatives thereof
  • A01N 37/44 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing at least one carboxylic group or a thio-analogue, or a derivative thereof, and a nitrogen atom attached to the same carbon skeleton by a single or double bond, this nitrogen atom not being a member of a derivative or of a thio-analogue of a carboxylic group, e.g. amino-carboxylic acids
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
  • A61K 31/201 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having one or two double bonds, e.g. oleic or linoleic acid
  • A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
  • A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
  • A61P 31/02 - Local antiseptics
  • A61P 31/04 - Antibacterial agents
  • A61K 31/14 - Quaternary ammonium compounds, e.g. edrophonium, choline

6.

Therapeutic compositions of undecylenic acid and arginine

      
Application Number 17461857
Grant Number 12383524
Status In Force
Filing Date 2021-08-30
First Publication Date 2021-12-16
Grant Date 2025-08-12
Owner Wintermute Biomedical, Inc. (USA)
Inventor
  • Rau, Thomas F.
  • Rogers, Geoffrey W.

Abstract

Compositions including a complex of fatty acids (e.g., including one or more C4 to C40 fatty acids, such as a C4 to C20 fatty acid) and one or more amino acids (and particularly one or more amino acids having electrically charged basic side chains, e.g., Arginine, Lysine, etc.) for use as an anti-pathogenic composition. These compositions may include the complex of fatty acid:amino acid having a lamellar supramolecular structure. In particular, described herein are therapeutic compositions of undecylenic acid:Arginine forming a complex of undecylenic acid and Arginine.

IPC Classes  ?

  • A61K 31/20 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid
  • A01N 33/12 - Quaternary ammonium compounds
  • A01N 37/06 - Unsaturated carboxylic acids or thio-analogues thereofDerivatives thereof
  • A01N 37/44 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing at least one carboxylic group or a thio-analogue, or a derivative thereof, and a nitrogen atom attached to the same carbon skeleton by a single or double bond, this nitrogen atom not being a member of a derivative or of a thio-analogue of a carboxylic group, e.g. amino-carboxylic acids
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 31/14 - Quaternary ammonium compounds, e.g. edrophonium, choline
  • A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
  • A61K 31/201 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having one or two double bonds, e.g. oleic or linoleic acid
  • A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
  • A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
  • A61P 31/02 - Local antiseptics
  • A61P 31/04 - Antibacterial agents

7.

THERAPEUTIC COMPOSITIONS

      
Application Number US2021025060
Publication Number 2021/202644
Status In Force
Filing Date 2021-03-31
Publication Date 2021-10-07
Owner WINTERMUTE BIOMEDICAL, INC. (USA)
Inventor
  • Rau, Thomas, F.
  • Rogers, Geoffrey, W.

Abstract

Compositions including a complex of fatty acids and amino acids in a 1:0.6 to about 1:1.6 forming lamellar supramolecular structures for use as an anti-pathogenic composition. Also described herein are antipathogenic composition comprising a mixture of a fatty acid: amino acid in a molar ratio of between about 1:0.6 to about 1:1.6; and a molar ratio of fatty acid: monoterpene/monoterpenoid between about 15:1 to 2:1.

IPC Classes  ?

  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
  • A61K 31/201 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having one or two double bonds, e.g. oleic or linoleic acid
  • A61P 31/04 - Antibacterial agents
  • A61P 31/12 - Antivirals

8.

Therapeutic compositions of decanoic acid and arginine

      
Application Number 16836893
Grant Number 11154524
Status In Force
Filing Date 2020-03-31
First Publication Date 2020-09-10
Grant Date 2021-10-26
Owner Wintermute Biomedical, Inc. (USA)
Inventor
  • Rau, Thomas F.
  • Rogers, Geoffrey W.

Abstract

Compositions including a complex of fatty acids (e.g., including one or more C4 to C40 fatty acids, such as a C4 to C20 fatty acid) and one or more amino acids (and particularly one or more amino acids having electrically charged basic side chains, e.g., Arginine, Lysine, etc.) for use as an anti-pathogenic composition. In particular, described herein are compositions of decanoic acid:Arginine in which the decanoic acid and Arginine for a complex having a lamellar supramolecular structure.

IPC Classes  ?

  • A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
  • A61K 31/201 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having one or two double bonds, e.g. oleic or linoleic acid
  • A61P 31/02 - Local antiseptics
  • A01N 33/12 - Quaternary ammonium compounds
  • A01N 37/06 - Unsaturated carboxylic acids or thio-analogues thereofDerivatives thereof
  • A01N 37/44 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing at least one carboxylic group or a thio-analogue, or a derivative thereof, and a nitrogen atom attached to the same carbon skeleton by a single or double bond, this nitrogen atom not being a member of a derivative or of a thio-analogue of a carboxylic group, e.g. amino-carboxylic acids
  • A61K 31/14 - Quaternary ammonium compounds, e.g. edrophonium, choline
  • A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
  • A61K 31/20 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid

9.

Therapeutic compositions of undecylenic acid and arginine

      
Application Number 16836881
Grant Number 11103475
Status In Force
Filing Date 2020-03-31
First Publication Date 2020-07-23
Grant Date 2021-08-31
Owner Wintermute Biomedical, Inc. (USA)
Inventor
  • Rau, Thomas F.
  • Rogers, Geoffrey W.

Abstract

Compositions including a complex of fatty acids (e.g., including one or more C4 to C40 fatty acids, such as a C4 to C20 fatty acid) and one or more amino acids (and particularly one or more amino acids having electrically charged basic side chains, e.g., Arginine, Lysine, etc.) for use as an anti-pathogenic composition. These compositions may include the complex of fatty acid:amino acid having a lamellar supramolecular structure. In particular, described herein are therapeutic compositions of undecylenic acid:Arginine forming a complex of undecylenic acid and Arginine.

IPC Classes  ?

  • A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
  • A61K 31/20 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid
  • A61K 31/201 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having one or two double bonds, e.g. oleic or linoleic acid
  • A61P 31/02 - Local antiseptics
  • A01N 33/12 - Quaternary ammonium compounds
  • A01N 37/06 - Unsaturated carboxylic acids or thio-analogues thereofDerivatives thereof
  • A01N 37/44 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing at least one carboxylic group or a thio-analogue, or a derivative thereof, and a nitrogen atom attached to the same carbon skeleton by a single or double bond, this nitrogen atom not being a member of a derivative or of a thio-analogue of a carboxylic group, e.g. amino-carboxylic acids
  • A61K 31/14 - Quaternary ammonium compounds, e.g. edrophonium, choline
  • A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds

10.

THERAPEUTIC COMPOSITIONS

      
Application Number US2019054044
Publication Number 2020/072479
Status In Force
Filing Date 2019-10-01
Publication Date 2020-04-09
Owner WINTERMUTE BIOMEDICAL, INC. (USA)
Inventor
  • Rau, Thomas, F.
  • Rogers, Geoffrey, W.

Abstract

Compositions of fatty acids (e.g., including one or more C4 to C40 fatty acids, such as a C4 to C20 fatty acid) and one or more amino acids (and particularly one or more amino acids having electrically charged basic side chains, e.g., Arginine, Lysine, etc.) for use as an anti-pathogenic composition. These compositions may find particular use as anti-bacterial and in some variations anti-viral, anti-fungal and anti-cancer compositions.

IPC Classes  ?

  • A61K 31/19 - Carboxylic acids, e.g. valproic acid
  • A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
  • A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
  • A61P 31/04 - Antibacterial agents

11.

Anti-pathogenic therapeutic compositions

      
Application Number 16485735
Grant Number 11065220
Status In Force
Filing Date 2018-02-13
First Publication Date 2020-02-13
Grant Date 2021-07-20
Owner Wintermute Biomedical, Inc. (USA)
Inventor
  • Hale, Weston J.
  • Rau, Thomas F.

Abstract

Therapeutic compounds useful for the treatment of pathogens including bacteria (gram positive and gram negative, mycobacteria), some fungi and viruses. The compounds described herein may include a mixture of therapeutically-effective amounts of a polar amino acid, a CI 1 fatty acid, and an anthraquinone. The invention further provides for the administration of the therapeutic compounds to a patient (e.g., a human) suffering from an infection.

IPC Classes  ?

  • A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
  • A61P 31/04 - Antibacterial agents
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
  • A61K 31/201 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having one or two double bonds, e.g. oleic or linoleic acid
  • A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers

12.

ANTI-PATHOGENIC THERAPEUTIC COMPOSITIONS

      
Application Number US2018018077
Publication Number 2018/148763
Status In Force
Filing Date 2018-02-13
Publication Date 2018-08-16
Owner WINTERMUTE BIOMEDICAL, INC. (USA)
Inventor
  • Hale, Weston, J.
  • Rau, Thomas, F.

Abstract

Therapeutic compounds useful for the treatment of pathogens including bacteria (gram positive and gram negative, mycobacteria), some fungi and viruses. The compounds described herein may include a mixture of therapeutically-effective amounts of a polar amino acid, a CI 1 fatty acid, and an anthraquinone. The invention further provides for the administration of the therapeutic compounds to a patient (e.g., a human) suffering from an infection.

IPC Classes  ?

  • A61K 36/708 - Rheum (rhubarb)
  • A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
  • A61K 31/201 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having one or two double bonds, e.g. oleic or linoleic acid
  • A61P 31/04 - Antibacterial agents

13.

Therapeutic compounds

      
Application Number 14760778
Grant Number 10195242
Status In Force
Filing Date 2014-01-27
First Publication Date 2015-12-24
Grant Date 2019-02-05
Owner Wintermute Biomedical, Inc. (USA)
Inventor
  • Hale, Weston J.
  • Rau, Thomas F.

Abstract

Rheum Officinale extract. The invention further provides for the administration of the therapeutic compounds to a patient (e.g., a human) suffering from a skin disease, infection, or wound.

IPC Classes  ?

  • A61K 36/00 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K 36/36 - Caryophyllaceae (Pink family), e.g. babysbreath or soapwort
  • A61K 36/70 - Polygonaceae (Buckwheat family), e.g. spineflower or dock
  • A61K 36/708 - Rheum (rhubarb)
  • A61K 8/97 - Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution from algae, fungi, lichens or plantsCosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution from derivatives thereof
  • A61K 8/36 - Carboxylic acidsSalts or anhydrides thereof
  • A61K 8/44 - Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfurSalts, esters or N-acylated derivatives thereof
  • A61Q 17/00 - Barrier preparationsPreparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
  • A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
  • A61K 31/201 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having one or two double bonds, e.g. oleic or linoleic acid

14.

THERAPEUTIC COMPOSITIONS

      
Document Number 03178309
Status Pending
Filing Date 2021-03-31
Owner WINTERMUTE BIOMEDICAL, INC. (USA)
Inventor
  • Rau, Thomas F.
  • Rogers, Geoffrey W.

Abstract

Compositions including a complex of fatty acids and amino acids in a 1:0.6 to about 1:1.6 forming lamellar supramolecular structures for use as an anti-pathogenic composition. Also described herein are antipathogenic composition comprising a mixture of a fatty acid: amino acid in a molar ratio of between about 1:0.6 to about 1:1.6; and a molar ratio of fatty acid: monoterpene/monoterpenoid between about 15:1 to 2:1.

IPC Classes  ?

  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
  • A61K 31/201 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having one or two double bonds, e.g. oleic or linoleic acid
  • A61P 31/04 - Antibacterial agents
  • A61P 31/12 - Antivirals

15.

THERAPEUTIC COMPOSITIONS

      
Document Number 03115050
Status In Force
Filing Date 2019-10-01
Grant Date 2025-09-16
Owner WINTERMUTE BIOMEDICAL, INC. (USA)
Inventor
  • Rau, Thomas F.
  • Rogers, Geoffrey W.

Abstract

Compositions of fatty acids (e.g., including one or more C4 to C40 fatty acids, such as a C4 to C20 fatty acid) and one or more amino acids (and particularly one or more amino acids having electrically charged basic side chains, e.g., Arginine, Lysine, etc.) for use as an anti-pathogenic composition. These compositions may find particular use as anti-bacterial and in some variations anti-viral, anti-fungal and anti-cancer compositions.

IPC Classes  ?

  • A61K 31/19 - Carboxylic acids, e.g. valproic acid
  • A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
  • A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
  • A61P 31/04 - Antibacterial agents